N
N Iikuni
Researcher at Eli Lilly and Company
Publications - 3
Citations - 204
N Iikuni is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Tabalumab & Placebo. The author has an hindex of 2, co-authored 3 publications receiving 168 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
David A. Isenberg,Michelle A. Petri,Kenneth C. Kalunian,Yoshiya Tanaka,Murray B. Urowitz,Robert W Hoffman,M Morgan-Cox,N Iikuni,M. Silk,Daniel J. Wallace +9 more
TL;DR: Tabalumab had biological activity—changes in anti-dsDNA, complement, B cells and immunoglobulins—consistent with BAFF pathway inhibition; safety profiles were similar with tabalumab and placebo; key clinical efficacy endpoints did not achieve statistical significance.
Journal ArticleDOI
OP0184 Efficacy and Safety of Tabalumab in Patients with Systemic Lupus Erythematosus (SLE): Results from 2 Phase 3, 52-Week, Multicenter, Randomized, Placebo-Controlled Trials
David A. Isenberg,Joan T. Merrill,Robert W Hoffman,Matthew D. Linnik,M Morgan-Cox,Melissa Veenhuizen,N Iikuni,C. Dickson,M. Silk,Daniel J. Wallace,Thomas Dörner +10 more
TL;DR: The safety profile of the tabalumab and pbo groups was similar across both trials, and Reduction in anti-dsDNA was observed as well as increases in complement C3 and C4 and reduction in total B cells and immunoglobulins (Ig).
Efficacy and safety of tabalumab in patients with systemic lupus erythematosus (sle): results from 2 phase 3, 52-week, multicenter, randomized, placebo-controlled trials
David A. Isenberg,Joan T. Merrill,Robert W Hoffman,Matthew D. Linnik,M Morgan-Cox,Melissa Veenhuizen,N Iikuni,C. Dickson,M. Silk,Daniel J. Wallace,T Doerner +10 more